Nose-to-brain drug delivery: Challenges and progress towards brain targeting in the treatment of neurological disorders

Raghav, Meenakshi; Gupta, Vaishnavi; Awasthi, Rajendra; Singh, Anurag; Kulkarni, Giriraj T.

doi:10.1016/j.jddst.2023.104756

Cited by 6 publications

(1 citation statement)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the intranasal route of delivery is being intensively developed for neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, etc. ), where the lack of effective treatment is an important current problem, and neurodevelopmental conditions (for example, autism spectrum disorders), which currently have no approved medication [ 47 ]. Indeed, intranasal administration of the neuropeptide oxytocin resulted in alleviating social shortfalls in children with autism spectrum disorders [ 48 , 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunotherapy with M2 Macrophage Secretome Ameliorates Language Impairments and Autistic-like Behavior in Children

Shevela,

Loginova,

Munkuev

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: The intranasal delivery of various neurotropic substances is considered a new attractive therapeutic approach for treating neuropathologies associated with neuroinflammation and altered regeneration. Specific language impairment (SLI) that arises as a result of damage to the cortical speech zones during the developmental period is one of the most common problems in preschool children, and it is characterized by persistent difficulties in the acquisition, understanding, and use of language. This study’s objective is to evaluate the efficacy and safety of intranasal immunotherapy using the M2 macrophage secretome as a rich source of immunoregulatory and neurotrophic factors for the treatment of severe language impairment in children. Methods: Seventy-one children (54 boys and 17 girls, aged 3 to 13 years) were recruited to participate in a clinical trial (NCT04689282) in two medical centers. The children were examined before, 1 month after, and 6 months after the start of therapy. In the vast majority of children (55/71), language impairment was associated with autistic-like symptoms and attention deficit hyperactivity disorder (ADHD). Results: Daily intranasal inhalations of M2 macrophage-conditioned medium (for 30 days) were well tolerated and led to a decrease in the severity of language impairments, autistic-like behavior, and ADHD symptoms. The clinical effect appeared within a month after the first procedure and persisted or intensified during a 6-month follow-up. Two-thirds of the children showed a clear clinical improvement, while the rest had less pronounced improvement. Conclusions: Thus, the use of the M2 macrophage secretome and its intranasal delivery is safe, well tolerated, and clinically effective in children with severe language impairments.

show abstract